0 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
Mobile engineering interviews focus heavily on platform-specific knowledge, UI/UX implementation, and mobile system architecture.. Explore key insights and preparation tips to help you excel in your interview process.
Mobile interviews emphasize UI components, data persistence, networking, and memory management specific to iOS/Android platforms.
Focus on Swift/Kotlin fundamentals and mobile-specific algorithms
Start PracticingDesign scalable mobile apps with offline capabilities, push notifications, and efficient data synchronization patterns.
App Architecture
MVVM, MVP, Clean Architecture
Data Sync
Offline-first, conflict resolution
Performance
Memory, battery, network optimization
Different companies emphasize different aspects of mobile development based on their product needs and scale.
Meta
Cross-platform performance and React Native expertise
Uber
Real-time location services and offline functionality
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers approximately 65% lower housing costs and overall living expenses compared to San Francisco, allowing mobile engineers to maximize their earning potential. With median home prices around $200K versus San Francisco's $1.4M+, your salary stretches significantly further while maintaining access to major East Coast markets.
Baltimore's mobile engineering market remains accessible with growing opportunities in fintech, healthcare tech, and government contracting. Less saturated than major tech hubs while offering strong career advancement potential.
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States